KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Non-Current Assets (2016 - 2025)

Pacira BioSciences (PCRX) has 16 years of Non-Current Assets data on record, last reported at $716.9 million in Q4 2025.

  • For Q4 2025, Non-Current Assets fell 11.31% year-over-year to $716.9 million; the TTM value through Dec 2025 reached $3.1 billion, down 16.91%, while the annual FY2025 figure was $716.9 million, 11.31% down from the prior year.
  • Non-Current Assets reached $716.9 million in Q4 2025 per PCRX's latest filing, down from $734.8 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $1.2 billion in Q1 2022 and bottomed at $533.3 million in Q2 2021.
  • Average Non-Current Assets over 5 years is $941.8 million, with a median of $1.0 billion recorded in 2024.
  • Peak YoY movement for Non-Current Assets: surged 126.49% in 2022, then fell 24.05% in 2024.
  • A 5-year view of Non-Current Assets shows it stood at $1.2 billion in 2021, then decreased by 2.19% to $1.2 billion in 2022, then fell by 10.02% to $1.1 billion in 2023, then decreased by 24.05% to $808.4 million in 2024, then fell by 11.31% to $716.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Non-Current Assets were $716.9 million in Q4 2025, $734.8 million in Q3 2025, and $791.6 million in Q2 2025.